



GUJARAT THEMIS BIOSYN LIMITED

CIN : L24230GJ1981PLC004878

REGD. OFFICE & FACTORY : 69/C GIDC INDUSTRIAL ESTATE
VAPI - 396 195, DIST. VALSAD, GUJARAT, INDIA

TEL : 0260-2430027 / 2400639 FAX : 0260-2400638

E-mail : gtblrediffmail.com / accounts@gtbl.co.in

F. TBL:BSE/qtr-1 result/2015-16

11th August, 2015

The Secretary,
BSE Ltd.
Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
MUMBAI 400 001

Company Stock Code : 506879

Dear Sir,

Sub : Unaudited Financial Result for the quarter ended 30th June, 2015

The Board of Directors at it's meeting held today, considered and approved Unaudited Financial Results for the quarter ended 30th June, 2015 together with Limited Review Report by Statutory Auditors of the Company thereon which were recommended by the Audited Committee.

A copy of the Unaudited result for the quarter ended 30th June, 2015 with Limited Review report is attached herewith.

Also attached herewith a press note in connection with the above.

Please take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,
For GUJARAT THEMIS BIOSYN LTD.

JAYAPAL. K
Compliance Officer

Encl : as above

GUJARAT THEMIS BIOSYN LIMITED

CIN: L24230GJ1981PLC004878

69/C, GIDC Industrial Estate, Vapi - 396 195, Dist. Valsad, Gujarat

Tel: +91 260 2430027 Fax: +91 260 2400639 E-mail: gtblmumbai@gtbl.in / admin@gtbl.co.in Wbsite: www.gtbl.in

PART I : Statement of Unaudited Financial Results for the quarter ended 30th June, 2015

		(Rs. in Lacs)			
	Particulars	Quarter Ended			Year Ended
		30-Jun-15	31-Mar-15	30-Jun-14	31-Mar-15
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations				
	(a) Net sales/income from operations (Net of excise duty)	826.61	804.89	763.54	3,144.02
	(b) Other operating income	-	-	-	-
	Total income from operations (net)	826.61	804.89	763.54	3,144.02
2	Expenses				
	(a) Cost of raw materials consumed	8.08	6.46	7.53	28.99
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expense	106.19	109.20	98.26	400.20
	(e) Depreciation and amortisation expense	28.99	31.96	36.33	137.54
	(f) Impairment of fixed assets	-	-	-	-
	(g) Other expenses	-	-	-	-
	i) Stores & Spares	44.44	55.35	39.57	177.10
	ii) Power	333.61	294.50	283.02	1,158.45
	iii) Fuel	95.44	104.00	97.39	410.99
	iv) Water	13.58	11.76	11.35	46.25
	v) Other Expenditure	67.76	100.92	62.42	295.25
	Total Expenses	698.08	714.14	635.86	2,654.77
3	Profit / (Loss) from operations before other income,finance costs and exceptional items(1-2)	128.53	90.74	127.67	489.25
4	Other income	1.56	2.09	4.22	8.88
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	130.09	92.83	131.89	498.13
6	Finance costs	7.49	8.17	13.21	38.72
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)	122.60	84.66	118.68	459.41
8	Exceptional items	-	-	-	-
9	Net Profit from ordinary activities before tax (7 + 8)	122.60	84.66	118.68	459.41
10	Tax expense	-	-	-	-
11	Net Profit from ordinary activities after tax (9 - 10)	122.60	84.66	118.68	459.41
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit for the period (11 + 12)	122.60	84.66	118.68	459.41



Particulars	Quarter Ended			Year Ended
	30/Jun/15	31/Mar/15	30/Jun/14	31/Mar/15
	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
14 Paid-up equity share capital Face Value Rs.5/- per share each	726.40	726.40	726.40	726.40
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				(804.93)
16.i Earnings per share (before extraordinary items) Face Value Rs.5/- per share each (not annualised):				
(a) Basic	0.84	0.58	0.82	3.16
(b) Diluted	0.84	0.58	0.82	3.16
16.ii Earnings per share (after extraordinary items) Face Value Rs.5/- per share each (not annualised):				
(a) Basic	0.84	0.58	0.82	3.16
(b) Diluted	0.84	0.58	0.82	3.16
PART II : Select information for the year ended 30th June, 2015				
A PARTICULARS OF SHAREHOLDING				
1 Public shareholding				
- Number of shares	3,632,957	3,632,957	2,209,957	3,632,957
- Percentage of shareholding	25.01%	25.01%	15.21%	25.01%
2 Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered				
- Number of shares	Nil	Nil	Nil	Nil
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
b) Non - encumbered				
- Number of shares	10,895,745	10,895,745	12,318,745	10,895,745
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%
Percentage of shares (as a % of the total share capital of the company)	74.99%	74.99%	84.79%	74.99%
B Particulars		Quarter ended 30-06-2015		
INVESTOR COMPLAINTS				
Pending at the beginning of the quarter		Nil		
Received during the quarter		-		
Disposed of during the quarter		-		
Remaining unresolved at the end of the quarter		Nil		



Notes :	
1	The above results were reviewed by the Audit Committee and approved by the Board of Directors at its their respective meetings held on 11th August 2015. The Statutory Auditors of the Company have carried out a limited review of the aforesaid results.
2	The Company is mainly engaged in the business of manufacturing Bulk Drugs. Hence, there is no separate reportable segment as per Accounting Standard - 17 (AS-17) "Segment Reporting".
3	In view of carry forward losses / unabsorbed depreciation of earlier years, company being a sick company and relief & concession granted by the BIFR, no provision for the Income Tax has been made.
4	In respect of Auditor's qualifications / observations in the Audit Report for the year ended 31st March, 2015 that, <ul style="list-style-type: none"> a) The outstanding balance as at 31st March, 2015, in respect of certain balances of trade receivables, deposits, loans & advances, liability for expenses, trade payables and creditors for capital expenditure, are subject to confirmation and adjustments necessary upon reconciliation if any, consequential impact thereof in the financial statements is not ascertainable. The Management does not expect any material variation in the financial statements. b) In view of sanction of Rehabilitation Scheme by the BIFR and also the Company has made profit for quarter ended 30th June 2015 and previous year 2014-15, 2013-14, 2012-13 & 2011-12, the accounts have been prepared on going concern basis, inspite of negative net worth as at 31st March, 2015 and working capital deficiency.
5	The Company is in the process of determining and identifying significant components of fixed assets as prescribed under the provisions of para 4(a) under the heading Notes after Part C in Schedule II of the Companies Act,2013 and the effect of the same would be taken in due course during the FY 2015-16. Management expects that this would not have a material impact on depreciation of the current quarter.
6	The figures of previous period / year have been regrouped / rearranged wherever necessary / practicable to conform to current period / year presentation.

By order of the Board of Directors
For GUJARAT THEMIS BIOSYN LTD.



[Signature]
Dr. DINESH PATEL
Chairman

Place : Mumbai
Date : August 11, 2015

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

Website: www.kjco.net * E-mail: kjco@kjco.net

6-B&C, Pil Court, 6th Floor,
111, M. Karve Road, Churchgate,
Mumbai - 400 020.
Tel.: (+91-22) 4311 5000
Fax: 4311 5050

12-B, Baldota Bhavan, 5th Floor,
117, M. Karve Road, Churchgate,
Mumbai - 400 020.
Tel.: (+91-22) 4311 6000
Fax: 4311 6060

Independent Auditors' Review Report

The Board of Directors,
Gujarat Themis Biosyn Limited,
Vapi.

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of 'Gujarat Themis Biosyn Limited' for the quarter ended June 30, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Accounting Standards specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement with the Stock Exchange including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHANDELWAL JAIN & CO.
Chartered Accountants
Firm's Regn. No. 105049W



(NARENDRA JAIN)
PARTNER

Membership No. 048725



Place: Mumbai
Date : August 11, 2015

GUJARAT THEMIS BIOSYN LIMITED

CIN : L24230GJ1981PLC004878

69/C GIDC Industrial Estate, Vapi – 396 195, Dist.Valsad, Gujarat


Tel : + 91 2602430027 Fax : +91 260 2400639 Email : gtblmumbai@gtbl.in / admin@gtbl.co.in.

Website : www.gtbl.in

PRESS NOTE

1. Gujarat Themis Biosyn Ltd. is pleased to announce operating income of Rs. 826.61 Lacs during the quarter ended 30th June, 2015 against Rs. 804.89 Lacs achieved during the quarter ended 31st March, 2015.
2. The net profit amounted to Rs. 122.60 Lacs during the quarter ended 30th June, 2015 against Rs. 84.66 Lacs recorded during the quarter ended March, 2015.
3. The company has earned EPS (Not annualized) of Rs. 0.84 per share of Rs. 5/- each against Rs. 0.58 for the quarter ended 31st March, 2015.
4. The net worth of the Company has become positive during the quarter ended 30th June, 2015 much ahead as envisaged in the Scheme of Rehabilitation approved by the BIFR. The approved scheme envisaged positive net worth during the year 2018-19.

For GUJARAT THEMIS BIOSYN LIMITED



Dr. DINESH PATEL
Chairman

